Initial Coagulation Markers in Patients with Kala-Azar Associated with Tranexamic Acid

Not Applicable

• Conditions: Visceral Leishmaniasis; Fibrinolysis; C01.610

• Registration Number: RBR-6xbgv9j
• Lead Sponsor: Instituto de Doenças Tropicais Nathan Portela - IDTNP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-04-28
• Last Update Posted: 29 May 2023
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with confirmed visceral leishmaniasis; both genders; without age restrictions, who agree to participate voluntarily by signing the Free and Informed Consent Term and the Minor's Assent Term, in patients aged between six and 18 years

Exclusion Criteria

Patients using anticoagulant or antiplatelet medication at the time of admission; recent diagnosis or history of thrombosis at any vascular site; congenital or acquired hemostasis disorders; need for dialysis, surgery or an invasive procedure; known or suspected hypersensitivity to any study drug; recent or past history of seizures; history of dengue fever or Severe Acute Respiratory Syndrome Coronavirus 2 infection in the last 30 days; having received specific anti-Leishmania treatment in the last 90 days; having received antifibrinolytic treatment in the last 48 hours or blood products in the last 360 hours

Study & Design

• Study Type: Intervention
• Study Design: Not specified